Hanmi Science Co., Ltd. (KRX:008930)

Market Cap	1.77T -26.3%
Revenue (ttm)	1.38T +5.0%
Net Income	136.01B +157.9%
EPS	2,007.42 +157.7%
Shares Out	67.71M
PE Ratio	13.00
Forward PE	n/a
Dividend	300.00 (1.15%)
Ex-Dividend Date	Mar 30, 2026

Volume	73,894
Open	26,350
Previous Close	26,100
Day's Range	26,250 - 28,400
52-Week Range	25,600 - 55,500
Beta	0.50
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About Hanmi Science

Hanmi Science Co., Ltd., through its subsidiaries, manufactures and sells pharmaceutical products in Korea and internationally. It develops drugs in the areas of diabetes and anti-cancer, as well as children's and adult’s bowel preparation and cold medicines, and cephalosporin antibiotics. The company also offers general foods, health functional foods, soy milk, and medical equipment. In addition, it offers automated drug management systems. The company sells its products through online and offline pharmacies. The company was formerly known as ...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 1973
• Employees: 476
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 008930

Financial Performance

In 2025, Hanmi Science's revenue was 1.36 trillion, an increase of 5.73% compared to the previous year's 1.28 trillion. Earnings were 118.37 billion, an increase of 99.20%.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jun 29, 2026

Data Sources Report a data error